Business
Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call
Developments to be Shared by Dr. Jack Reich, Director, Dr. Bankole A. Johnson, Chief Medical Officer, William B. Stilley, III, Chief Executive Officer, and
About this update from Adial Pharmaceuticals, Inc
[{"type":"text","content":"Developments to be Shared by Dr. Jack Reich, Director, Dr. Bankole A. Johnson, Chief Medical Officer, William B. Stilley, III, Chief Executive Officer, and Joseph A. M. Truluck, Chief Financial OfficerCHARLOTTESVILLE, VA / ACCESSWIRE / July 28, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) (\"Adial\"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it will host a conference call at 11:00 AM, Eastern Time on Thursday, July 30, 2020, to provide material updates regarding the Company's business and operations and landmark ONWARD™ pivotal Phase 3 trial.The conference call will be available via telephone by dialing toll free 844-407-9500 for U.S. callers or + 862-298-0850 for international callers, or on the Company's Investors section of the website: https://ir.adialpharma.com/.A webcast replay will be available on the Company's Investor section of the website, https://ir.adialpharma.com/, through July 30, 2021. A telephone replay of the call with be available approximately one hour following the call, through Thursday, August 13, 2020 and can be accessed by dialing 877-481-4010 for U.S. callers or + 919-882-2331 for international callers and entering conference ID: 36297.About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. www.adialpharma.comNote on Forward-looking Statement...